Document Detail

Racial differences in heart failure therapeutics.
MedLine Citation:
PMID:  19945062     Owner:  NLM     Status:  In-Process    
Heart failure in African Americans has a phenotype that is distinct from that in non-African Americans and that demonstrates increased importance of hypertensive etiologies. Trial data demonstrate that African Americans receive significant benefit from beta blockade. Despite differences in the heart failure phenotype, therapy of heart failure in African Americans remains largely the same as in white heart failure cohorts, with the notable exception of the added benefits provided by combination of hydralazine and isosorbide dinitrate (HYD-ISDN), now regarded as highly indicated therapy by both the Heart Failure Society of America and the American College of Cardiology/American Heart Association heart failure guideline committees. HYD-ISDN in fixed combination is the first cardiovascular drug approved for a single ethnic or racial subset--self-designated African Americans.
David Ishizawar; Clyde Yancy
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Heart failure clinics     Volume:  6     ISSN:  1551-7136     ISO Abbreviation:  -     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231934     Medline TA:  Heart Fail Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  65-74     Citation Subset:  IM    
Cardiovascular Institute, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Natriuretic peptides and the genomics of left-ventricular hypertrophy.
Next Document:  Genomic and proteomic analysis of myocarditis and dilated cardiomyopathy.